Exhaled Breath Pattern After Medication Intake, in OSA Patients, or Other Pulmonary DiseasesNCT05456009
Exhaled Breath Analysis in Human Subjects
An observational study of Exhaled Breath Pattern After Medication Intake, in OSA Patients, or Other Pulmonary Diseases, run by University of Zurich at 1 site in Switzerland.
Trial summary
Identification of exhaled breath pattern of human subjects Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Exhaled Breath Pattern After Medication Intake, in OSA Patients, or Other Pulmonary Diseases
- How many people
- 1,500 participants
- Where
- 1 siteSwitzerland
- Study dates
- 19 Feb 2019to 1 Mar 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Population of human subjects with heart failure, dementia syndrome, parkinson disease, obstructive sleep apnea, chronic obstructive pulmonary disease, pneumonia, specific medication use.
Who may be able to join
- >= 18 years
- Informed consent
Who cannot join
- specific exclusion criteria for different subgroups
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
University Hospital Zurich
Zurich, Canton of Zurich, 8091
Malcolm Kohler, MD, malcolm.kohler@usz.ch
Noriane Sievi, MSc, +41442559815, noriane.sievi@usz.ch
About this study
Official title: Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Human Subjects
Identification of exhaled breath pattern of human subjects
Read the detailed description
Breath analysis with mass spectormetry as a non-invasive method to identfy exhaled breath patterns.
- Conditions
- Exhaled Breath Pattern After Medication Intake, in OSA Patients, or Other Pulmonary Diseases
- Being tested
- No intervention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
No intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
Exhaled breath pattern
mass spectrometric profile of exhaled breath pattern of human subjects
Measured: baseline
Secondary outcomes (7)
Chemical structure of exhaled breath molecules
The identification of the chemical structure of exhaled breath molecules
Measured: baseline
Body fluids
The correlations of identified molecules in exhaled breath with body fluids
Measured: baseline
Disease marker
The correlation of a distinct disease marker with a breath print or breath feature
Measured: baseline
Distinguish between disease
The use of a breath print to distinguish between disease and/or health state
Measured: baseline
Health state
The correlation of breath prints to subjective health state and/or quality of life
Measured: baseline
Medication
Response to medication and toxicity as a function of blood/breath drug concentrations
Measured: baseline
Excretion of drugs
Correlation between lung function and the excretion of drugs in exhaled breath
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2022
- Study start19 Feb 2019
- Primary completion1 Mar 2030 (estimated)
- Study completion1 Mar 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Exhaled Breath Pattern After Medication Intake, in OSA Patients, or Other Pulmonary DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Collaborators
- Deep Breath Intelligence (DBI)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05456009
- Sponsor's protocol ID
- 2019-00030
- Other IDs
- 2019
- Status last verified
- May 2026
- First submitted
- 30 Jun 2022
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: if requested
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Human Subjects
- ClinicalTrials.gov ID
- NCT05456009
- Acronym / sponsor ID
- 2019-00030
- Conditions
- Exhaled Breath Pattern After Medication Intake, in OSA Patients, or Other Pulmonary Diseases
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Collaborators
- Deep Breath Intelligence (DBI)
- Study start
- 19 Feb 2019 (actual)
- Primary completion
- 1 Mar 2030 (estimated)
- Study completion
- 1 Mar 2030 (estimated)
- First posted
- 13 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Identification of exhaled breath pattern of human subjects
Detailed description
Breath analysis with mass spectormetry as a non-invasive method to identfy exhaled breath patterns.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Population of human subjects with heart failure, dementia syndrome, parkinson disease, obstructive sleep apnea, chronic obstructive pulmonary disease, pneumonia, specific medication use.
Key inclusion criteria (2 listed)
- >= 18 years
- Informed consent
Key exclusion criteria (1 listed)
- specific exclusion criteria for different subgroups
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionNo intervention | Other | – |
Primary outcome
Exhaled breath pattern
Time frame: baseline
mass spectrometric profile of exhaled breath pattern of human subjects
7 secondary outcomes
Chemical structure of exhaled breath molecules
Time frame: baseline
Body fluids
Time frame: baseline
Disease marker
Time frame: baseline
Distinguish between disease
Time frame: baseline
Health state
Time frame: baseline
Medication
Time frame: baseline
Excretion of drugs
Time frame: baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Individual participant dataSharing planned: Undecided. if requested
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Exhaled Breath Pattern After Medication Intake, in OSA Patients, or Other Pulmonary Diseases, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Malcolm Kohler, MD (+41442551111, malcolm.kohler@usz.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exhaled breath pattern (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.